in the neonate. It is a major cause of neonatal mortality and morbidity and is associated with neurodevelopmental impairment.
I
n preterm infants, neonates less than 37 weeks' gestation, with respiratory distress syndrome (RDS), poor ventilation-perfusion matching, and elevated pulmonary vascular resistance commonly present. 1 Both pulmonary artery pressure and oxygenation have been thought to improve with inhaled nitric oxide (iNO) therapy. Preterm infants are at risk for bronchopulmonary dysplasia (BPD), a long-term pulmonary disability in neonates characterized by inflammation and scarring in the lungs due to mechanical ventilation. If the hypothesis that the use of iNO therapy reduces required ventilator support, then consequential lung injury will decline and the frequency of BPD will follow. 2 Bronchopulmonary dysplasia is an extremely important chronic medical illness because it leads to arrested lung development
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presence of hyperoxia. 10 Inhaled NO minimizes oxidant stress by the downregulation of lung-derived cytokines, suggesting a possible decline in brain injury. 8, 9 Hence, the purpose of this article is to determine the efficacy and safety of iNO therapy in preterm infants with severe RDS and respiratory failure along with its neuroprotectant factors. A literature review of all full-text, English language studies in PubMed, CINAHL, and the Cochrane Library between 2005 and 2010 was used.
MECHANISM OF ACTION
In its inhaled form, NO causes relaxation of smooth muscles and vasodilation. 11 This process is activated as iNO quickly diffuses from the alveolar space to the vascular smooth muscle cell, binding with and increasing cyclic guanosine monophosphate. This then triggers a surge of GMP-dependent protein kinases, resulting in an efflux of calcium from cells.
11 These pulmonary effects caused by iNO help uphold normal vascular permeability and maintain low pulmonary arterial pressures. Inhaled NO helps decrease ventilation-perfusion mismatch and improve oxygenation because it restructures pulmonary blood flow as it is preferentially carried to ventilated areas of the lung. 12 In a dose-dependent manner, NO systemically disrupts platelet and leukocyte functions, increasing and decreasing the inflammatory processes, and also increases urine output. But, these systemic vascular effects have demonstrated to be insignificant and iNO adverse effects are uncommon. 12 Miller and Rhine 12 describe iNO toxicity as the formation of methemoglobin, hemoglobin whose iron component is altered so that it does not carry oxygen well, nitric dioxide, a potent oxidant, and peroxynitrite, a powerful oxidant and proinflammatory mediator. Life-threatening adverse effects of acute withdrawal from iNO include rebound pulmonary hypertension and hypoxemia. Inhaled NO must be weaned slowly.
BACKGROUND
In the term and late preterm infants, iNO has been used for the treatment of persistent pulmonary hypertension with hypoxic respiratory failure. 11 In preterm infants with respiratory failure secondary to RDS and other pulmonary diseases, it was considered for use soon thereafter. According to Miller and Rhine, 12 RDS seen in prematurity is linked with postponed postnatal circulatory adaptation characterized by pulmonary hypertension, systemic hypotension, and prolonged ductus arteriosus patency. Martin and Walsh 13 proposed that iNO may have several effects on the developing lung parenchyma, bronchi, and vasculature between 25 and 28 weeks' gestation. Proposed effects include increased growth and surfactant function with decreased elastin production and inflammation, increased bronchodilation, and decreased airway smooth muscle proliferation. 13 Ballard and colleagues 14 discovered that iNO may, in fact, improve surfactant function briefly in infants weighing less than 1250 g receiving a lengthy course of iNO. No evidence of adverse effects is detected in iNO therapy outcomes on surfactant protein composition and recovery. The concern for possible development or progression of intraventricular hemorrhage (IVH) in the delicate premature brain must also be considered, given the consequences of iNO therapy on platelet function.
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ANIMAL STUDIES
To better understand the various roles that iNO may have in the developing lung, animal studies were preformed. A study performed in a premature rat model with BPD demonstrated that iNO therapy prolonged survival, decreased fibrin deposition, enhanced alveolar growth by lessening septal thickness, and reduced the influx of leukocytes and capillary-alveolar leakage. 16 Inhaled NO-induced downregulation of genes affecting inflammation, coagulation, fibrinolysis, and cell cycle regulation has been confirmed in mRNA testing as well as fibroblast growth factor receptor-4 upregulation. This type of fibroblast growth factor membrane receptor is involved in secondary septation and alveolar enlargement. 16 Continuous, low-dose iNO therapy administered immediately after birth to a BPD lamb model for an extended 3-week course of mechanical ventilation showed significantly decreased airway resistance, less airway smooth muscle growth, and greater alveolarization but detected no variance in pulmonary vascular resistance. 17 This study revealed iNO augments alveolar development, while preserving composition and function of airway smooth muscle. Premature infants with BPD can be greatly influenced by both of these actions.
McCurnin and colleagues 18 performed a study in a baboon model of BPD. At the end of the study, these researchers observed that beginning iNO in premature baboons within 1 hour of life and sustaining it for 14 days resulted in decreased pulmonary artery pressure, larger incidence of spontaneous closure of the ductus arteriosus, better lung compliance and expiratory resistance, and increased lung DNA content and cell proliferation, and maintained lung growth. Possible modification of alveolarization by iNO was suggested in the study as the excessive elastin was normalized and secondary neural crest cell development was present.
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HUMAN STUDIES
A Cochrane meta-analysis of all randomized and quasi-randomized studies in preterm babies with respiratory disease has been published comparing the administration effects of iNO on a control group, with and without placebo gas. 2 Although the preferred approach to evaluate the value of a given treatment is a meta-analysis, the differing characteristics of all the trials are a limiting factor to its usefulness. 19 There is a wide spectrum of studies regarding iNO use in the preterm neonate ranging from rescue therapy of hypoxic respiratory failure because of persistent pulmonary hypertension of the newborn or severe BPD to a prophylactic use in order to prevent BPD. 2 The trials to date can be grouped into 3 different categories, depending on the entry criteria for iNO use: initiation within the first 3 days of life based on oxygen criteria, also termed as rescue therapy, routine use in preterm intubated patients, or later enrollment based on an increased risk for BPD (see Table 1 ).
The multicenter study headed by Van Meurs et al 15 randomly assigned neonates less than 34 weeks' gestation, with a birth weight of 401 to 1500 g, and with respiratory failure more than 4 hours after treatment with surfactant to iNO at 5 to 10 parts per million (ppm) or placebo gas. The incidence of death or BPD was 80% in the iNO-treated group compared with 82% in the placebo group, and the rate of BPD alone was 60% in the iNO-treated group versus 68% in the placebo group. Death and BPD rates were reduced for infants with birth weights greater than 1000 g without an increase in the rate of IVH as suggested in the post hoc analyses, whereas infants who were treated with iNO and weighed 1000 g or less had a higher mortality and increased rate of severe intracranial hemorrhage. 15 At the recommendation of the data safety and monitoring committee, the study was terminated early as the frequency of severe IVH or periventricular leukomalacia (PVL) appeared to be significantly greater in the treatment group with no benefit on the primary outcome of reducing rates of BPD or death. 12 This difference was not statistically significant at the end of the trial. Eleven rescue treatment trials were compared in the Cochrane meta-analysis. 2 The results of the meta-analysis of this subgroup showed identical findings to the study by Van Meurs et al. 15 The analysis showed no significant effect on survival to discharge, death prior to 36 weeks' postmenstrual age, incidence of BPD, combined outcome of death or BPD, or overall IVH frequency. Although the effect was not significant upon conclusion, the studies showed a movement toward increased incidence of severe IVH, defined as grades 3 and 4, and in PVL as well. Moreover, improvement in oxygenation was noted within 2 hours of the iNO therapy initiation by multiple studies. 2 Within the past 5 years, only 1 study has been done regarding the routine use of iNO in preterm infants. The study by Kinsella and colleagues 20 enrolled newborns who were 34 weeks' gestational age or less and had respiratory failure requiring mechanical ventilation. Newborns were randomly assigned to receive either iNO (5 ppm) or placebo gas for 21 days or until extubation, with stratification according to birth weight (500 to 749 g, 750 to 999 g, or 1000 to 1250 g). A composite of death or BPD at 36 weeks' postmenstrual age was the primary efficacy outcome. Intracranial hemorrhage, PVL, and ventriculomegaly were secondary safety outcomes of the study. The incidence of death or BPD between patients receiving iNO and those receiving placebo showed no significant difference (71.6% vs 75.3%, p ϭ .24). However, when comparing treatment and placebo in infants weighing between 1000 and 1250 g at birth, iNO therapy showed a reduction in the incidence of BPD (29.8% vs 59.6%, p ϭ .001). Inhaled NO treatment did reduce the combined end point of intracranial hemorrhage, PVL, or ventriculomegaly (17.5% vs 23.9%, p ϭ .03) and of PVL alone (5.2% vs 9.0%, p ϭ .048). Overall, low-dose iNO did not reduce the incidence of BPD among premature infants with respiratory failure, except among infants with a birth weight of at least 1000 g, but it did reduce the overall chance of brain injury 20 (see Table 2 ).
The final category of the later enrollment based on BPD-risk subgroup defines Ballard and colleagues' 14 study. The trial was a multicenter, randomized, stratified, double-blind, placebo-controlled trial of iNO involving infants with a birth weight of 1250 g or less requiring ventilator support between 7 and 21 days of age. For a minimum of 24 days, treated infants received decreasing concentrations of NO. Survival without BPD at 36 weeks' postmenstrual age was the primary outcome of the study. The rate of survival without BPD at 36 weeks' postmenstrual age was 43.9% in the group receiving NO and 36.8% in the placebo group (p ϭ .042). The infants who were treated with iNO received supplemental oxygen therapy for a shorter time (p ϭ .006) and were discharged sooner (p ϭ .04). The study confirmed that iNO therapy in premature infants improves the pulmonary outcome for those who are at risk for BPD when it is initiated between 7 and 21 days of age and has no evident short-term adverse effects.
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NEURODEVELOPMENTAL OUTCOMES
Preterm infants are at a high risk for neurodevelopmental impairment, including blindness, deafness, cerebral palsy, and global cognitive delay, 21 as well as more subtle cognitive deficits, such as language delay, learning disabilities, and attention and executive function abnormalities. 4 Little progress has been made in developing treatments or creating preventative measures, despite an increasing awareness of the risk factors leading to abnormal neurodevelopmental outcomes. The impact of iNO remains controversial in regard to the development of the central nervous system. In past studies, an increase was noted in the incidence of intracranial hemorrhage in critically ill preterm neonates receiving iNO therapy. 15 Nitric oxide was demonstrated to increase bleeding time and inhibit platelet aggregation in many initial iNO trials. 19 Although a trend for an increased incidence of severe IVH or PVL was noted in early rescue studies, there was no significant difference between control and iNO groups. 4 The varied entry criteria, lack of cranial ultrasound scans before study entry, short duration of iNO treatment, and more critically ill babies being enrolled in these trials are examples of the limitations to analyses of the results. In comparison with the early rescue trials, the early prophylactic trials showed a reduction of neurological injury while the late therapy trials showed no progression of this outcome.
The study by Mestan and colleagues 22 noted a momentous decrease in the composite outcome of neurodevelopmental disability, defined as cerebral palsy, bilateral blindness, bilateral hearing loss, and greater than 2 SD lower than the mean of Bayley scores of infant development. There were more mature and fewer critically ill neonates in this singlecenter study who were not at high risk for this outcome. Nevertheless, this is the first trial to date to report 2-year follow-up of iNO therapy outcomes on neurodevelopmental status giving reassurance of no potential harm with iNO in this patient population.
The results of the Neonatal Ventilation With Inhaled Nitric Oxide Versus Ventilatory Support Without Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure study, also known as the INNOVO trial for short, by Huddy et al 23 were still pending when the results of the Mestan et al 22 study were released. When the INNOVO study was published, its investigators reported the rates of major disability from iNO therapy given to ventilated premature infants at 1 year of age weighing less than 1250 g, which showed no difference between the groups. Severe disability was defined as no/minimal head control or inability to sit unsupported or no/minimal responses to visual stimuli. There was no difference between the groups (7 of the 55 patients who received iNO therapy vs 2 of the 53 patients who did not receive iNO therapy could not sit unsupported at 1 year).
The most recent study to date by Walsh and colleagues 24 reported follow-up neurodevelopmental outcomes at 2 years of age in ventilated preterm infants treated with iNO. The study concluded that exposure to 24 days of iNO treatment initiated at 20 ppm between 7 and 21 days in ventilated preterm infants is both safe and effective, with improved survival free of BPD and no adverse effects on growth or neurodevelopmental status at 2 years of age.
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CONCLUSION
Despite the thousands of babies being enrolled in iNO trials, there are still questions to be answered about clinical management of iNO in preterm newborns. The available data for the use of iNO in the management of preterm neonates suggest that a beneficial effect depends on the patient population, duration of therapy, and underlying pathological condition. 4 The early and late uses of iNO in the management of preterm neonates cannot be recommended until BPD results and long-term neurodevelopmental follow-up data show consistent, beneficial findings. The use of iNO as rescue therapy for infants weighing less than 1 kg is confounded by a patient population at high risk for an adverse neurological outcome. Although endogenous NO is important for lung growth, there is little evidence that an exogenous supply of NO achieves that goal. Only in a small population of infants weighing between 1000 and 1250 g at birth did iNO therapy in one study show a reduction in the incidence of BPD. 20 The potential role of iNO needs to be further defined and the abundant laboratory evidence needs to be translated to beneficial clinical outcomes before it can be used by health care providers as a standard of care.
